MDGL Stock Summary and Trading Ideas (Madrigal Pharmaceuticals | NASDAQ:MDGL)

Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

Madrigal Pharmaceuticals trades on the NASDAQ stock market under the symbol MDGL.

As of April 19, 2024, MDGL stock price declined to $212.04 with 610,466 million shares trading.

MDGL has a beta of 1.82, meaning it tends to be more sensitive to market movements. MDGL has a correlation of 0.11 to the broad based SPY ETF.

MDGL has a market cap of $4.45 billion. This is considered a Mid Cap stock.

In the last 3 years, MDGL stock traded as high as $322.67 and as low as $52.33.

The top ETF exchange traded funds that MDGL belongs to (by Net Assets): VTI, VB, IWM, VBR, XBI.

MDGL has underperformed the market in the last year with a price return of -26.7% while the SPY ETF gained +21.2%. MDGL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -5.4% and -12.2%, respectively, while the SPY returned +4.3% and -3.5%, respectively.

MDGL support price is $215.88 and resistance is $228.64 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MDGL stock will trade within this expected range on the day.